This article was originally published on The Conversation.   Currently 53% of the population doesn’t trust the pharmaceutical industry. Most of this mistrust is caused by the numerous scandals that have hit the industry in recent years, often related to controversial clinical-trial practices, data misuse or hidden secondary effects for commercialised drugs. Overall, patients have[…]

This article was originally published on La Tribune.   Comment une technologie née de la finance – la blockchain – peut aider l’industrie pharmaceutique à réaliser des essais cliniques protecteurs des patients. Quelque 53 % de la population mondiale ne fait pas confiance à l’industrie pharmaceutique. Cette méfiance s’explique pour une grande partie par les nombreux scandales qui ont[…]

This article was originally published on 23 Consulting.   For many years, it seemed obvious that protecting and insuring the integrity of patient data required the use of centralized systems. Such systems do offer a certain degree of control over the use of the information but they also represent a single point of failure that is[…]

This article was originally published on 23 Consulting.   BLOCKCHAIN FOR THE SUPPLY CHAIN TOPS OTHER USE CASES IN THE PHARMACEUTICAL INDUSTRY   80% of pharmaceutical companies developing a blockchain strategy positioned the supply chain use case as their main focus.   Blockchain technology has characteristics that are particularly interesting for tracing and tracking medical products:[…]

This article was originally published on 23 Consulting.   DR. DAVID MANSET Dr. David Manset is CEO of Be-Studys, a Swiss digital transformation company specialized in blockchain, big data and AI, part of the Be-Ys group. Over the last decade, he architected large-scale international big data and blockchain platforms, including My Health My Data. MHMD is an[…]